Study on the Expression and Clinical Significance of KLF1 in Acute Myeloid Leukemia

doi:10.19586/j.2095-2341.2025.0074

Current Biotechnology ›› 2025, Vol. 15 ›› Issue (5): 904-912.DOI: 10.19586/j.2095-2341.2025.0074

• Articles • Previous Articles Next Articles

Study on the Expression and Clinical Significance of KLF1 in Acute Myeloid Leukemia

Jiajia YUAN(), Huan SHAO()

Department of Pharmacy，Wuxi No. 2 People's Hospital（Jiangnan University Medical Center），Jiangsu Wuxi 214002，China

Received:2025-07-01 Accepted:2025-08-18 Online:2025-09-25 Published:2025-11-11
Contact: Huan SHAO

Abstract

Abstract:

Acute myeloid leukemia （AML） is a kind of malignant hematopoietic disorders characterized by abnormal proliferation and differentiation arrest of myeloid cells. The transcriptome information and clinical information of patients in the database were used to analyze the expression of Krueppel-like factor 1（KLF1） in AML patients. "Survival" and "Survminer" packages were used for survival analysis. The patients were divided into two groups by high and low expression of KLF1， and differential gene analysis was performed to analyze the functional enrichment. The protein-protein interaction networks （PPI） diagram of differentially expressed genes was constructed by STRING online database， and the core genes were screened by Cytoscape software. The IC₅₀ value of potential drugs was predicted by pRRophetic， and medicines targeting low expression of KLF1 were screened. It was found that the expression of KLF1 was significantly down-regulated in AML patients， and the low expression of KLF1 was associated with poor prognosis. A total of 1 017 differential expression genes （DEGs） were screened between the low and high expression groups of KLF1， and the enrichment analysis of DEGs functional pathways showed that the immune response-related pathways of the KLF1 low expression group were screened. CD4 is the hub gene with low expression of KLF1 leading to poor prognosis in AML. Drug susceptibility predictions suggested a number of inhibitors associated with cell cycle and kinases. The results suggested that low expression of KLF1 can predict the poor prognosis of AML， and further provide new solutions for the diagnosis and treatment of AML.

Key words: acute myeloid leukemia, Krueppel-like factor 1, differential expression genes, orotein-protein interaction networks

摘要：

急性髓系白血病（acute myeloid leukemia，AML）是一类以髓系细胞异常增殖及分化阻滞为特征的恶性造血性疾病。利用数据库中患者的转录组信息和临床信息分析Krueppel样因子1(Krueppel like factor 1，KLF1)在AML患者中的表达情况，使用R语言中的“Survival”和“Survminer”包进行生存分析。将患者分为KLF1高表达和低表达2组，进行差异基因功能富集分析。采用STRING在线数据库构建差异基因的蛋白互作网络图，利用Cytoscape软件筛选出核心基因，通过“pRRophetic”包预测潜在药物IC₅₀值，并对靶向KLF1低表达药物进行筛选。结果发现，KLF1在AML患者中表达显著下调，且KLF1低表达与不良预后相关。在KLF1低表达组和高表达组之间共筛选出1 017个差异基因，差异基因功能分析表明KLF1低表达组富集在免疫应答相关通路。筛选出CD4是KLF1低表达导致AML预后不良的关键基因。药物敏感性预测表明KLF1低表达细胞对细胞周期、激酶相关抑制剂具有敏感性。研究结果提示KLF1低表达可预测AML不良预后，可进一步为AML的诊断和治疗提供新的方案。

关键词: 急性髓系白血病, KLF1, 差异基因表达, 蛋白互作网络

CLC Number:

Q814.4

Jiajia YUAN, Huan SHAO. Study on the Expression and Clinical Significance of KLF1 in Acute Myeloid Leukemia[J]. Current Biotechnology, 2025, 15(5): 904-912.

袁佳佳, 邵欢. KLF1在急性髓系白血病中的表达及临床意义研究[J]. 生物技术进展, 2025, 15(5): 904-912.

Figures/Tables 5

Fig. 1 The relationship of expression of KLF1 in AML and adverse clinical features

Fig. 2 Low expression of KLF1 predicts worse prognosis in AML

Fig. 3 Functional enrichment analysis based on KLF1 expression

Fig. 4 Identification of CD4 as the hub gene connected with KLF1 expression

Fig. 5 Drug sensitivity analysis of AML cells with low KLF1 expression

References 33

[1]	KONOPLEVA M, POLLYEA D A, POTLURI J, et al.. Efficacy and biological correlates of response in a phase Ⅱ study of venetoclax monotherapy in patients with acute myelogenous leukemia[J]. Cancer Discov., 2016, 6(10): 1106-1117.
[2]	XIE G, IVICA N A, JIA B, et al.. CAR-T cells targeting a nucleophosmin neoepitope exhibit potent specific activity in mouse models of acute myeloid leukaemia[J]. Nat. Biomed. Eng., 2021, 5(5): 399-413.
[3]	DOSSA R G, CUNNINGHAM T, SOMMERMEYER D, et al.. Development of T-cell immunotherapy for hematopoietic stem cell transplantation recipients at risk of leukemia relapse[J]. Blood, 2018, 131(1): 108-120.
[4]	CHRISTOPHER M J, PETTI A A, RETTIG M P, et al.. Immune escape of relapsed AML cells after allogeneic transplantation[J]. N. Engl. J. Med., 2018, 379(24): 2330-2341.
[5]	HU Q, SUN W, WANG J, et al.. Conjugation of haematopoietic stem cells and platelets decorated with anti-PD-1 antibodies augments anti-leukaemia efficacy[J]. Nat. Biomed. Eng., 2018, 2(11): 831-840.
[6]	MAGANTI H B, JRADE H, CAFARIELLO C, et al.. Targeting the MTF2-MDM2 axis sensitizes refractory acute myeloid leukemia to chemotherapy[J]. Cancer Discov., 2018, 8(11): 1376-1389.
[7]	SUDA K, KIM J, MURAKAMI I, et al.. Innate genetic evolution of lung cancers and spatial heterogeneity: analysis of treatment-Naïve lesions[J]. J. Thorac. Oncol., 2018, 13(10): 1496-1507.
[8]	PERKINS A, XU X, HIGGS D R, et al.. Krüppeling erythropoiesis: an unexpected broad spectrum of human red blood cell disorders due to KLF1 variants[J]. Blood, 2016, 127(15): 1856-1862.
[9]	LEY T J, MILLER C, DING L, et al.. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia[J]. N. Engl. J. Med., 2013, 368(22): 2059-2074.
[10]	CONSORTIUM T G. The GTEx Consortium atlas of genetic regulatory effects across human tissues[J]. Science, 2020, 369(6509): 1318-1330.
[11]	VIVIAN J, RAO A A, NOTHAFT F A, et al.. Toil enables reproducible, open source, big biomedical data analyses[J]. Nat. Biotechnol., 2017, 35(4): 314-316.
[12]	GOLDMAN M J, CRAFT B, HASTIE M, et al.. Visualizing and interpreting cancer genomics data via the Xena platform[J]. Nat. Biotechnol., 2020, 38(6): 675-678.
[13]	HAFERLACH T, KOHLMANN A, WIECZOREK L, et al.. Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group[J]. J. Clin. Oncol., 2010, 28(15): 2529-2537.
[14]	LOVE M I, HUBER W, ANDERS S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2[J/OL]. Genome Biol., 2014, 15(12): 550[2025-08-07]. .
[15]	CARBON S, DOUGLASS E, GOOD B M. The gene ontology resource: enriching a gold mine[J]. Nucleic Acids Res., 2021, 49(D1): 325-334.
[16]	YU G, WANG L G, HAN Y, et al.. Clusterprofiler: an R package for comparing biological themes among gene clusters[J]. OMICS, 2012, 16(5): 284-287.
[17]	SHANNON P, MARKIEL A, OZIER O, et al.. Cytoscape: a software environment for integrated models of biomolecular interaction networks[J]. Genome Res., 2003, 13(11): 2498-2504.
[18]	GEELEHER P, COX N, HUANG R S. pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels[J/OL]. PLoS ONE, 2014, 9(9): e107468[2025-08-01]. .
[19]	DING C, SHAN Z, LI M, et al.. Characterization of the fatty acid metabolism in colorectal cancer to guide clinical therapy[J]. Mol. Ther. Oncolytics, 2021, 20: 532-544.
[20]	HAYASHI Y, GOYAMA S, LIU X, et al.. Antitumor immunity augments the therapeutic effects of p53 activation on acute myeloid leukemia[J/OL]. Nat. Commun., 2019, 10(1): 4869[2025-08-01]. .
[21]	DINARDO C D, TIONG I S, QUAGLIERI A, et al.. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML[J]. Blood, 2020, 135(11): 791-803.
[22]	XIA T, KONNO H, AHN J, et al.. Deregulation of STING signaling in colorectal carcinoma constrains DNA damage responses and correlates with tumorigenesis[J]. Cell Rep., 2016, 14(2): 282-297.
[23]	GILLINDER K R, ILSLEY M D, NÉBOR D, et al.. Promiscuous DNA-binding of a mutant zinc finger protein corrupts the transcriptome and diminishes cell viability[J]. Nucleic Acids Res., 2017, 45(3): 1130-1143.
[24]	KULCZYNSKA K, BIEKER J J, SIATECKA M. A krüppel-like factor 1 (KLF1) mutation associated with severe congenital dyserythropoietic Anemia alters its DNA-binding specificity[J/OL]. Mol. Cell. Biol., 2020, 40(5): e00444-19[2025-08-01]..
[25]	BINDER S, LUCIANO M, HOREJS-HOECK J. The cytokine network in acute myeloid leukemia (AML): a focus on pro- and anti-inflammatory mediators[J]. Cytokine Growth Factor Rev., 2018, 43: 8-15.
[26]	NECHIPORUK T, KURTZ S E, NIKOLOVA O, et al.. The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells[J]. Cancer Discov., 2019, 9(7): 910-925.
[27]	HOU P, WU C, WANG Y, et al.. A genome-wide CRISPR screen identifies genes critical for resistance to FLT3 inhibitor AC220[J]. Cancer Res., 2017, 77(16): 4402-4413.
[28]	DRENBERG C D, SHELAT A, DANG J, et al.. A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML[J/OL]. Nat. Commun., 2019, 10(1): 2189[2025-08-07]. .
[29]	YADAV M, SINGH A K, KUMAR H, et al.. Epidermal growth factor receptor inhibitor cancer drug gefitinib modulates cell growth and differentiation of acute myeloid leukemia cells via histamine receptors[J]. Biochim. Biophys. Acta, 2016, 1860(10): 2178-2190.
[30]	SOUCY T A, SMITH P G, MILHOLLEN M A, et al.. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer[J]. Nature, 2009, 458(7239): 732-736.
[31]	MCCUBREY J A, STEELMAN L S, ABRAMS S L, et al.. Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy[J]. Leukemia, 2008, 22(4): 708-722.
[32]	SIGAUD R, RÖSCH L, GATZWEILER C, et al.. The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models[J]. Neuro. Oncol., 2023, 25(3): 566-579.
[33]	YONG J X, CAI S Q, ZENG Z L. Targeting NAD⁺metabolism: dual roles in cancer treatment[J/OL]. Front. Immunol. 2023, 14: 1269896[2025-08-21]. .

Study on the Expression and Clinical Significance of KLF1 in Acute Myeloid Leukemia

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 5

References 33

Related Articles 7

Recommended Articles

Metrics

Comments

[1]	Yiwen LU, Yiyi DING, Nini GUO, Wanling HUANG, Jingwen XU-ZHANG, Peiwen ZHANG, Nan WANG, Qian REN, Xiaotong MA. Effects and Mechanisms of TWIST1 on Mitochondrial Function and Chemoresistance in Acute Myeloid Leukemia Cells [J]. Current Biotechnology, 2026, 16(1): 190-195.
[2]	Yiming LIU, Leling XIE, Haiyan XING, Kejing TANG, Min WANG, Qing RAO. Anti-leukemia Effect of Chimeric Antigen Receptor T Cells Targeting CD74 Positive Leukemia Cells [J]. Current Biotechnology, 2024, 14(3): 501-505.
[3]	Wanling HUANG, Wenqi ZHU, Nini GUO, Nan WANG, Qian REN, Xiaotong MA. Effects of NRG4 on Proliferation, Apoptosis and Cell Cycle of Acute Myeloid Leukemia Cells [J]. Current Biotechnology, 2023, 13(2): 305-310.
[4]	Yueming ZHANG, Yaqin LUO, Wei ZHENG, Jie XU, Xueyan DONG, Shanchen LI, Jingyi WANG. Differential Expression Profiles of mRNA and Non-coding RNA and CeRNA Regulatory Network Analysis of Acute Myeloid Leukemia [J]. Current Biotechnology, 2023, 13(1): 146-153.
[5]	Ben XU, Rui QIN, Hang XIANG, XU Jingshu, Zilong LIAO, Jinping XIANG. Study on the Inhibition of Ailanthone on Malignant Biological Behavior of Acute Myeloid Leukemia Cells [J]. Current Biotechnology, 2022, 12(5): 769-777.
[6]	XU Jie, WANG Kefei, WEI Xiaojing, GONG Lixin, JIAO Yang, QIU Lugui, HAO Mu^*. Expression and Prognostic Significance of SCHIP1 in Acute Myeloid Leukemia: Analysis Based on Bioinformatics [J]. Curr. Biotech., 2020, 10(4): 417-425.
[7]	XU Wen, LUAN Xin-hong*, CAO Zhong-zan, LIU Mei, Gao Ming. Application Progress of Suppression Subtractive Hybridization in Screening Differentially Expressed Genes of the Poultry [J]. journal1, 2012, 2(5): 341-344.